Hillemanns P, Thaler C, Kimmig R
Klinik und Poliklinik für Frauenheilkunde und Geburtshilfe, Klinikum Grosshadern, Ludwig-Maximilians-Universität München, Deutschland.
Gynakol Geburtshilfliche Rundsch. 1997;37(4):179-90. doi: 10.1159/000272853.
Infection with human papillomavirus (HPV) is the major factor in the genesis of cervical intraepithelial (CIN) and invasive neoplasia. However, screening is still based upon cytology and further diagnostic investigation relies on colposcopy with punch biopsy. In this review, recent studies are evaluated with regard to consequences for optimal screening and management strategies of CIN. In summary, exfoliative cytology is still widely considered as the method of choice for population screening. Primary HPV DNA screening proves equivalent or superior to cytology only in populations with a low prevalence of HPV infections. Preliminary data from serological HPV tests are less promising. Cytological diagnosis of HPV infection may be verified by HPV testing. Recognizing high oncogenic risk viruses in CIN 1 may help to reduce the control period from 24 to 12 months and may lead to immediate therapy for CIN 2 lesions. However, further prospective studies evaluating the cost-effectiveness of HPV DNA tests in German-speaking countries are necessary.
人乳头瘤病毒(HPV)感染是宫颈上皮内瘤变(CIN)和浸润性肿瘤发生的主要因素。然而,筛查仍基于细胞学检查,进一步的诊断调查则依赖于阴道镜检查及活检。在本综述中,对近期有关CIN最佳筛查和管理策略的研究进行了评估。总之,脱落细胞学检查仍被广泛认为是人群筛查的首选方法。仅在HPV感染患病率较低的人群中,原发性HPV DNA筛查被证明等同于或优于细胞学检查。血清学HPV检测的初步数据前景不太乐观。HPV感染的细胞学诊断可通过HPV检测进行验证。识别CIN 1中具有高致癌风险的病毒可能有助于将监测期从24个月缩短至12个月,并可能导致对CIN 2病变立即进行治疗。然而,有必要在德语国家进行进一步的前瞻性研究,以评估HPV DNA检测的成本效益。